What are the indications for cimepilimab? What types of disease treatments is it suitable for?

Cemiplimab is a humanized anti-PD-1 (programmed death receptor-1) monoclonal antibody mainly used to treat certain types of cancer. The mechanism of action of PD-1 inhibitors is to restore the immune recognition and killing ability of T cells against cancer cells by blocking the binding of PD-1 to its ligands, thereby enhancing the body's anti-tumor immune response. The indications of cimepilimab mainly involve some refractory or advanced tumors, especially patients with poor response to other treatment methods.

First, the earliest approved indication for cimepilimab was advanced or metastatic cutaneous squamous cell carcinoma (CSCC). This is a highly aggressive form of non-melanoma skin cancer that is particularly common in people who are immunocompromised or chronically exposed to UV rays. For patients with locally advanced or metastatic CSCC, traditional treatments (such as surgery or radiotherapy) may not be able to completely clear the tumor. However, the PD-1 inhibitory effect of cimepilimab can enhance the body's anti-tumor immune response, improve survival rate, and achieve long-term remission in some patients.

Secondly, cimepilimab is also approved for the treatment of non-small cell lung cancer (NSCLC). This drug can be used as a first-line monotherapy option for patients with locally advanced or metastatic NSCLC with high PD-L1 expression levels (TPS ≥ 50%). Compared with traditional chemotherapy, PD-1 inhibitors can reduce unnecessary side effects and improve treatment tolerance and survival rate. In clinical trials, cimepilimab has shown good efficacy in the treatment of NSCLC patients with high PD-L1 expression, making it one of the important treatment options for such patients.
In addition, cimepilimab is also approved for the treatment of Baszek's disease (BCC, basal cell carcinoma), especially in patients who have received gefitinib (a Hedgehog signaling pathway inhibitor) but whose disease has progressed or is intolerant. Basal cell carcinoma is one of the most common skin cancers, and although most cases are curable with surgery, there are fewer treatment options for patients with locally advanced or metastatic BCC. The immunotherapy modality cimepilimab offers new hope for these patients, especially in cases where surgery and radiotherapy are not suitable.
In general, cimepilimab, as a PD-1 inhibitor, is mainly suitable for patients with certain types of skin cancer (such as advanced CSCC, BCC) and lung cancer (NSCLC). As more clinical studies are conducted, the potential of this drug in other tumor types, such as cervical cancer or other solid tumors, is also being explored. For certain patient groups, cimepilimab offers a new immunotherapy option that may increase survival and improve quality of life.
Reference: https://www.libtayohcp.com/